Navigation Links
New Program Developed in the Fight Against Feline Aids
Date:11/4/2009

LTCI NOW is created by Imulan to inform cat owners about fast, new treatment program for FIV and FELV

New York, N.Y. (PRWEB) November 4, 2009 -- IMULAN BioTherapeutics, LLC has developed the LTCI NOW program in an effort to educate cat owners about the new, fast way to get LTCI for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Like Human Immunodeficiency Virus (HIV), FIV and FeLV are retroviral infections that can cause immunosuppression.

The LTCI NOW program will not only inform pet owners about the first and only USDA-conditionally approved treatment for FIV and FeLV, but also provide a truly simple and fast way to either obtain the pioneered product through their current veterinarian or through a network of current LTCI-using veterinarians across the country (Imulan’s ‘Treatment Network’) . LTCI’s sole focus is to make things as easy as possible on the pet owner; all they need to do is go to the website, and provide their veterinarian with the LTCI NOW brochure – the vet takes it from there. LTCI, or Lymphocyte T-Cell Immunomodulator, is only available through veterinarians, and is a major step forward in combating these highly serious and potentially fatal feline illnesses, which can lead to severe immune suppression (like HIV), anemia, and increased risk of other infections. In addition to fostering awareness about the feline illnesses and treatment with LTCI, IMULAN’s veterinarians will also offer free case consultations with the pet owner’s veterinarian.

According to Dr. Craig Woods, CEO of IMULAN, "IMULAN's LTCI NOW program is designed to make the process of getting LTCI for cats infected with FeLV and FIV as easy as possible. IMULAN has streamlined the process because time is of the essence for many of these patients, who often are very sick. FeLV and FIV remain devastating diseases, and the more veterinarians and owners are aware of the available options, the more effective our profession will be at managing these diseases.”

The LTCI NOW Program was established to further the awareness of these feline diseases. The goal for the program is to make the process as simple as possible for pet owners, allowing them easy access to information LTCI so they are informed in discussions with their veterinarian.

IMULAN BioTherapeutics, LLC is a privately held bioscience company, working to develop immune-based treatments for various life threatening animal diseases. With technologies that are able to modulate cells that coordinate immune response and inflammation, IMULAN is a leader in developing first-in-class technologies for veterinary medicine. LTCI, approved by the United States Department of Agriculture, is IMULAN’s first commercial product manufactured by T-Cyte Therapeutics, Inc. LTCI has received a conditional license from the United States Department of Agriculture, additional efficacy and potency studies are underway.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3148704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
2. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
3. SemBioSys updates Apo AI development program
4. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
5. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Celebrity Designer Ty Pennington to Host ADHD Experts on Call Program
10. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Program Developed in the Fight Against Feline Aids
(Date:2/28/2017)... Massachusetts and NEW YORK , ... Biologics License Application accepted by the FDA for avelumab  ... the disease has metastasized   ... Germany , in the US and ... the US Food and Drug Administration (FDA) has accepted for ...
(Date:2/27/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Food and Drug Administration (FDA) has accepted the ... for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 ... acute pain in a medically supervised setting. The ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as ... private label organic services. , The first organic product is Organic 18 Percent Layer ... Dynamite Marketing, which owns the facility. , Catalyst already has received the Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned from her ... several cities, she gained a number of delicious recipes and new techniques to share ... South Africa’s Western Cape province. It is internationally renowned for its incredible wine ...
Breaking Biology Technology:
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
Breaking Biology News(10 mins):